Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12758622 | 1.00 | TYMS (0.65) | TYMSPOLB | |
| SCHEMBL17117806 | 0.93 | TYMS (0.74) | TYMS | |
| SCHEMBL335865 | 0.93 | TYMS (0.74) | TYMS | |
| SCHEMBL3235048 | 0.93 | TYMS (0.74) | TYMS | |
| SCHEMBL19389397 | 0.90 | TYMS (0.63) | TYMSPOLB | |
| SCHEMBL12758590 | 0.90 | TYMS (0.63) | TYMSPOLB | |
| SCHEMBL5692280 | 0.88 | POLB (0.77) | TYMSPOLB | |
| SCHEMBL13117353 | 0.88 | POLB (0.77) | TYMSPOLB | |
| SCHEMBL13223520 | 0.88 | POLB (0.77) | TYMSPOLB | |
| SCHEMBL13026822 | 0.88 | LMNA (0.67) | TYMSPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209695-A1 | Pharmaceutical Compositions for High-Capacity Targeted Delivery | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2019-07-11 | — | — | US | disclosed |
| US-10105446-B2 | Pharmaceutical compositions for high-capacity targeted delivery | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180016601-A1 | Methods for Modulating Genome Editing | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2018-01-18 | — | — | US | disclosed |
| US-20170014521-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2017-01-19 | — | — | US | disclosed |
| US-9486533-B2 | Pharmaceutical compositions for high-capacity targeted delivery | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160145619-A1 | MULTIVALENT APTAMER COMPLEXES | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2016-05-26 | — | — | US | disclosed |
| US-9284559-B2 | Multivalent aptamer complexes | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150094359-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2015-04-02 | — | — | US | disclosed |
| US-8940885-B2 | Cytotoxic nucleotides for targeted therapeutics | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2694042-A2 | ACTIVATED NUCLEOSIDE ANALOG CONJUGATES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20140017330-A1 | Activated Nucleoside Analog Conjugates and Methods of Use Thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2012138731-A2 | ACTIVATED NUCLEOSIDE ANALOG CONJUGATES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20110213135-A1 | Cytotoxic Nucleotides for Targeted Therapeutics | GMEINER WILLIAM H | 2011-09-01 | — | — | US | disclosed |
| US-20100261781-A1 | MULTIVALENT APTAMER COMPLEXES | GMEINER WILLIAM H | 2010-10-14 | — | — | US | disclosed |
| US-20080026947-A1 | Cytotoxic nucleotides for targeted therapeutics | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209695-A1 | Pharmaceutical Compositions for High-Capacity Targeted Delivery | EPHA2, CD2BP2, ADGRE5 | TYMS 251/4885POLB 3317/4885 |
| US-10105446-B2 | Pharmaceutical compositions for high-capacity targeted delivery | EPHA2, CD2BP2, ADGRE5 | TYMS 251/4885POLB 3317/4885 |
| US-20150094359-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | EPHA2, CD2BP2, ADGRE5 | TYMS 251/4885POLB 3317/4885 |
| US-20170014521-A1 | PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY | EPHA2, CD2BP2, ADGRE5 | TYMS 251/4885POLB 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.